TY - JOUR
T1 - Electroconvulsive therapy (ECT) for moderate-severity major depression among the elderly
T2 - Data from the pride study
AU - for the CORE/PRIDE workgroup
AU - Østergaard, Søren D.
AU - Speed, Maria S.
AU - Kellner, Charles H.
AU - Mueller, Martina
AU - McClintock, Shawn M.
AU - Husain, Mustafa M.
AU - Petrides, Georgios
AU - McCall, William V.
AU - Lisanby, Sarah H.
N1 - Funding Information:
The PRIDE study, which provided data for this analysis, was supported by the following grants from the National Institute of Mental Health : U01MH055495 , U01MH081362 , U01MH086127 , U01MH086130 , U01MH08612005 , U01MH084241 , and U01MH086122 . The National Institute of Mental Health had no influence on the design of this secondary data analysis, the interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Funding Information:
Dr. Østergaard and Dr. Speed report no conflicts of interest. Dr. Kellner has previously received grant support from the National Institute of Mental Health ; he receives fees from UpToDate, Psychiatric Times and Northwell Health; he receives royalties from Cambridge University Press. Dr. McClintock has received research support from the National Institutes of Health and he is a consultant to Pearson. Dr. Husain reports research grant support from: the National Institute of Health, the National Institute of Mental Health, the National Institute of Drug Abuse, the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the National Alliance for Research on Schizophrenia, Stanley Medical Foundation, Cyberonics, Neuronetics (past), and St. Jude Medical/Abbott. Dr. Petrides reports grants from the National Institute of Mental Health and support for clinical trials from St. Jude Medical, Alkermes, Lundbeck, Proteus, and the Stanley Foundation. Dr. McCall receives research support from MECTA Corp, Vistagen, Merck and PCORI, is a paid scientific advisor for Sage, Jazz, and Janssen pharmaceutical companies and receives royalties from Wolters Kluwer. Dr. Lisanby has received grant support from the Brain and Behavior Research Foundation , the Stanley Medical Research Foundation, Neosync, Nexstim, NIH, and Brainsway. The opinions expressed in this article are the author's own and do not reflect the views of the National Institutes of Health, the Department of Health and Human Services, or the United States government.
Funding Information:
The PRIDE study, which provided data for this analysis, was supported by the following grants from the National Institute of Mental Health: U01MH055495, U01MH081362, U01MH086127, U01MH086130, U01MH08612005, U01MH084241, and U01MH086122. The National Institute of Mental Health had no influence on the design of this secondary data analysis, the interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: Electroconvulsive therapy (ECT) is usually reserved for treatment of severe major depressive disorder (MDD), but may be equally effective in the treatment of moderate-severity MDD. This possibility, however, has only been studied to a very limited extent. We therefore investigated the efficacy of ECT after stratifying patients into severe MDD and moderate-severity MDD. Methods: We used data from the Prolonging Remission in Depressed Elderly (PRIDE) study, in which 240 patients (≥60 years) with MDD were treated with right unilateral ultrabrief pulse ECT, combined with venlafaxine. We used the six-item core depression subscale (HAM-D6) of the Hamilton Depression Rating Scale to define depression severity. Participants with baseline total scores ≥12 on the HAM-D6 were considered to have severe MDD, while those with HAM-D6 total scores <12 were considered to have moderate-severity MDD. Results: Among the participants with severe MDD and moderate-severity MDD, the mean change in the HAM-D6 total score from baseline to endpoint was -8.2 (95% confidence interval (95%CI) = -7.5; -9.0, paired t-test: p < 0.001) and -5.9 (95%CI = -5.1; -6.6, paired t-test: p < 0.001), respectively. A total of 63% of those with severe MDD and 75% of those with moderate-severity MDD achieved remission (HAM-D6 total score ≤4) (Pearson's 2-sample chi-squared test of difference between groups: p = 0.27). Limitations: The PRIDE study was not designed to address this research question. Conclusions: ECT combined with venlafaxine appears to be an effective treatment for moderate-severity MDD. It may be appropriate to expand the indications for ECT to include patients with moderate-severity MDD.
AB - Background: Electroconvulsive therapy (ECT) is usually reserved for treatment of severe major depressive disorder (MDD), but may be equally effective in the treatment of moderate-severity MDD. This possibility, however, has only been studied to a very limited extent. We therefore investigated the efficacy of ECT after stratifying patients into severe MDD and moderate-severity MDD. Methods: We used data from the Prolonging Remission in Depressed Elderly (PRIDE) study, in which 240 patients (≥60 years) with MDD were treated with right unilateral ultrabrief pulse ECT, combined with venlafaxine. We used the six-item core depression subscale (HAM-D6) of the Hamilton Depression Rating Scale to define depression severity. Participants with baseline total scores ≥12 on the HAM-D6 were considered to have severe MDD, while those with HAM-D6 total scores <12 were considered to have moderate-severity MDD. Results: Among the participants with severe MDD and moderate-severity MDD, the mean change in the HAM-D6 total score from baseline to endpoint was -8.2 (95% confidence interval (95%CI) = -7.5; -9.0, paired t-test: p < 0.001) and -5.9 (95%CI = -5.1; -6.6, paired t-test: p < 0.001), respectively. A total of 63% of those with severe MDD and 75% of those with moderate-severity MDD achieved remission (HAM-D6 total score ≤4) (Pearson's 2-sample chi-squared test of difference between groups: p = 0.27). Limitations: The PRIDE study was not designed to address this research question. Conclusions: ECT combined with venlafaxine appears to be an effective treatment for moderate-severity MDD. It may be appropriate to expand the indications for ECT to include patients with moderate-severity MDD.
UR - http://www.scopus.com/inward/record.url?scp=85086472236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086472236&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2020.05.039
DO - 10.1016/j.jad.2020.05.039
M3 - Article
C2 - 32663942
AN - SCOPUS:85086472236
SN - 0165-0327
VL - 274
SP - 1134
EP - 1141
JO - Journal of affective disorders
JF - Journal of affective disorders
ER -